Thursday, February 13, 2020 9:08:07 PM
flipper44,
Wish I could help with all the angst but poker isn't played with all the cards laid out for everyone to see along the way. The bears have been trying to get NWBO to show their cards longer than most of the longs and longs found ways to defend not doing so. Now we are at the point where an explanation is in order based on the maturity of the data and the length of the process to date. The question remains whether or not a conflicting business interest is in play. If there is, that ought to be disclosed without going into specifics. Then again I think by, or at, the ASM there will be a turning point for NWBO because investors are becoming very motivated to find answers and until they get them financing will be more difficult.
As much as we might want to be the players we only are on the sidelines remotely offering NWBO the capacity to play the game but sentiment for doing so is being impacted by NWBO's relationship with their investors. As long as I don't see researchers and employees wanting to distance themselves from NWBO or making comments that demonstrate a lack of unity then NWBO gets the benefit of the doubt by me. I would think members of the SAB might be being questioned quite often and comments monitored closely for any dissension. I can't imagine a day goes by without those closest to this trial being asked something about it by somebody. True sentiment finds a way to be expressed and reported at some point. In the mean time we have a combo trial utilizing L and for "some reason" bears chose to create doubt about whether or not it was L being used in the combo. Gee, I Wonder why. Best wishes.
Wish I could help with all the angst but poker isn't played with all the cards laid out for everyone to see along the way. The bears have been trying to get NWBO to show their cards longer than most of the longs and longs found ways to defend not doing so. Now we are at the point where an explanation is in order based on the maturity of the data and the length of the process to date. The question remains whether or not a conflicting business interest is in play. If there is, that ought to be disclosed without going into specifics. Then again I think by, or at, the ASM there will be a turning point for NWBO because investors are becoming very motivated to find answers and until they get them financing will be more difficult.
As much as we might want to be the players we only are on the sidelines remotely offering NWBO the capacity to play the game but sentiment for doing so is being impacted by NWBO's relationship with their investors. As long as I don't see researchers and employees wanting to distance themselves from NWBO or making comments that demonstrate a lack of unity then NWBO gets the benefit of the doubt by me. I would think members of the SAB might be being questioned quite often and comments monitored closely for any dissension. I can't imagine a day goes by without those closest to this trial being asked something about it by somebody. True sentiment finds a way to be expressed and reported at some point. In the mean time we have a combo trial utilizing L and for "some reason" bears chose to create doubt about whether or not it was L being used in the combo. Gee, I Wonder why. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
